Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK receives positive top-line results from sirukumab phase III programme supporting regulatory filings for rheumatoid arthritis in 2016
GSK today announced it has received positive top-line results from the phase III programme investigating sirukumab
-
Comic Relief and GSK form five-year partnership to fight malaria and strengthen health systems
A five-year partnership to fight malaria and improve health in five countries has today been launched by Comic Relief and GSK.
-
GSK receives European marketing authorisation for Nucala® (mepolizumab) in 31 countries
GSK announced that EMA has granted marketing authorisation for Nucala® as an add-on treatment for severe refractory eosinophilic asthma
-
GSK announces start of phase III study of sirukumab in Giant Cell Arteritis
GSK announced that dosing has commenced in a phase III study evaluating sirukumab.
-
GSK receives European marketing authorisation to expand indication for Volibris® in treatment of pulmonary arterial hypertension
GSK today announced that the European Commission has approved a variation to expand the current therapeutic indication for Volibris®
-
GSK announces positive results from phase III BLISS-SC study of Benlysta® (belimumab) administered subcutaneously in patients with systemic lupus erythematosus
GSK announces positive results from phase III BLISS-SC study of Benlysta® (belimumab) in patients with systemic lupus erythematosus
-
GSK’s Nucala® (mepolizumab) receives approval from US FDA
First anti-IL5 treatment for adults and adolescents with severe asthma with an eosinophilic phenotype
-
ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy
ViiV ,Pfizer and Shionogi today announced that the Phase IIb study LATTE 2 (NCT02120352) met its primary endpoint at 32 weeks
-
GSK and Merck to study immunotherapy combination as potential cancer treatment
Phase I human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, Keytruda®
-
GSK profiles innovative R&D portfolio to investors
40 potential new medicines and vaccines offer opportunity to drive long-term performance and deliver new benefits to patients and consumers
-
Results announcement for the third quarter 2015
Q3 sees continued progress in execution of Group strategy Sales of £6.1 billion (+11% CER) and core EPS of 23.0p (-13% CER)
-
GSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over
GSK today announced that the second pivotal phase III study of its candidate vaccine Shingrix™ successfully met its primary objective
-
GSK provides update on LATITUDE-TIMI 60 (losmapimod cardiovascular study)
GSK announced that its losmapimod phase III study, review of data from part A,3,503 patients did not indicate efficacy against larger part B
-
GSK’s Advair® Diskus® achieves primary endpoint in LABA safety study of patients with asthma
GlaxoSmithKline plc (GSK) today announced results from the ‘LABA’ (long acting beta2-agonist) safety study, AUSTRI (SAS115359).
-
GSK receives CHMP positive opinion to expand indication for Volibris® in pulmonary arterial hypertension
GSK receives CHMP positive opinion to expand indication for Volibris® in pulmonary arterial hypertension
-
GSK announces positive new data comparing Incruse® Ellipta® to tiotropium and glycopyrronium in patients with COPD
GSK announced positive results from comparing umeclidinium to two available bronchodilator treatments when used by patients with COPD.
-
GSK submits regulatory application for chlorhexidine gel for the prevention of umbilical cord infections in newborn babies
GSK announced it's submitted an application to EMA for antiseptic chlorhexidine gel for the prevention omphalitis in newborn babies.
-
GSK presents post-hoc analysis of Anoro® Ellipta® data assessing markers of COPD deterioration compared to tiotropium or placebo using a novel composite endpoint
GSK and THRX today announced data presented by GSK at the European Respiratory Society (ERS) International Congress (poster PA1001)
-
Regulatory update: GSK and Theravance announce intention to file Relvar® Ellipta® for COPD in Japan
GSK and THRX announced intention to file sJNDA for Relvar® Ellipta® for the treatment of COPD with the Japanese authority during the Q12016.
-
GSK receives positive CHMP opinion in Europe for novel anti-IL5 biological Nucala (mepolizumab) for the treatment of patients with severe refractory eosinophilic asthma
GSK today announced that the CHMP of EMA issued a positive opinion recommending marketing authorisation for mepolizumab